Brigatinib

ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
( 1, 2.1 )

Side effects, and when to stop

The following adverse reactions are discussed in greater detail in other sections of the prescribing information:

Interstitial Lung Disease (ILD)/Pneumonitis
Hypertension
Bradycardia
Visual Disturbance
Creatine Phosphokinase (CPK) Elevation
Pancreatic Enzymes Elevation
Hepatotoxicity
Hyperglycemia
Photosensitivity

Who should not take it

None.

Storing it

Store at controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) (see USP).

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Brigatinib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/brigatinib
APA 7th: sofidex. (2026, August 2). Brigatinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/brigatinib
AMA 11th: Brigatinib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/brigatinib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.